EGFR and non-small cell lung carcinoma: Following approvals in a later treatment setting, the first-line administration of EGFR TKIs became standard in 2009 with the approval of gefitinib [8], in patients with NS-NSCLC harboring an EGFR deletion 19 or L858R substitution, followed by the approval of erlotinib [9] and afatinib [5].